Röth A, et al. Blood. 2020.
PiaSky^® (crovalimab) 170mg/mL solution for injection Summary of Product Characteristics. F-Hoffmann-La Roche; 2024.
Overton P, et al. Patients Prefer Adherence. 2021;15:811–834.
Bektas M, et al. J Manag Care Spec Pharm. 2020;26:S14–S20.
Scheinberg P, et al. Am J Hematol. 2024;99:1757–1767.
Röth A, et al. Am J Hematol. 2024;99:1768–1777.
Bittner B, et al. BioDrugs. 2018;32:425–440.
Kulasekararaj A, et al. EHA 2024; poster presentation [poster P839].
Scheinberg P, et al. ASH 2024; poster presentation [abs p4078].
Sampei Z, et al. Int J Mol Sci. 2024;25:11679.
Ueda Y, et al. Ann Hematol. 2025;1–10.
Weiss DJ, et al. Nat Med. 2020;26:1835–1838.
Hirth W, et al. ISPOR 2024; poster presentation [poster OP7].
Ultomiris^™ (ravulizumab-cvwz) Prescribing Information. Boston MA: Alexion Pharmaceuticals, Inc; 2024.
Soliris^® (eculizumab) Prescribing information. Boston, MA: Alexion Pharmaceuticals, Inc; 2024.
Heald A, et al. Int J Clin Pract. 2021;75:e14341.
Peffault de Latour R, et al. Semin Hematol. 2022;59:38–46.
Shah N, et al. Paroxysmal Nocturnal Hemoglobinuria. Available at: https://www.ncbi.nlm.nih.gov/books/NBK562292/#:~:text=Epidemiology,to%2099%20years.%5B2%5D. Accessed July 2025.
Arnold LM, et al. Blood. 2008;112:4671.
Bril V, et al. J Comp Eff Res. 2024;13:e230171.
Teriou L, et al. EHA 2023; poster presentation [abs P783].
Araten D, et al. Blood. 2024;144:3706–3707.
Food and Drug Administration. PiaSky (crovalimab-akkz) new drug application integrated review. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761388Orig1s000IntegratedR.pdf. Accessed July 2025.

People with PNH face many challenges:	PiaSky® can help alleviate the lifetime burden of PNH:

People with PNH face many challenges:

PiaSky® can help alleviate the lifetime burden of PNH: